Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor

BACKGROUND: Evobrutinib is an oral, central nervous system (CNS)-penetrant and highly selective covalent Bruton’s tyrosine kinase inhibitor under clinical development for patients with relapsing multiple sclerosis (RMS). OBJECTIVE: To investigate the effect of evobrutinib on immune responses in seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-Or, Amit, Cross, Anne H, Cunningham, Anthony L, Hyvert, Yann, Seitzinger, Andrea, Gühring, Hans, Drouin, Elise E, Alexandri, Nektaria, Tomic, Davorka, Montalban, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580670/
https://www.ncbi.nlm.nih.gov/pubmed/37626477
http://dx.doi.org/10.1177/13524585231192460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580670/
https://www.ncbi.nlm.nih.gov/pubmed/37626477
http://dx.doi.org/10.1177/13524585231192460

Ejemplares similares